US denies bid to expand morning-after pill sales
December 7, 2011 by Kerry Sheridan in Medications
US regulators on Wednesday rejected a drug company's request to make emergency contraception available over the counter to consumers of all ages instead of by prescription to those under 17.
The rare move, which saw one government secretary overrule another at the 11th hour, was blasted by pro-choice advocates but hailed by conservatives who said girls 12-17 need to see a doctor before getting the morning-after pill.
At issue was a drug called Plan B One-Step, made by Pennsylvania-based Teva Pharmaceuticals which had petitioned the US Food and Drug Administration to make it available on drugstore shelves to anyone over 12.
The pill can reduce the chance of pregnancy if taken within 72 hours of unprotected sex. It is currently available by prescription only to people under 17 in the United States.
Those over 17 can ask for it at a pharmacy counter without a doctor's prescription.
An FDA division that monitors drugs and reviews new applications, the Center for Drug Evaluation and Research (CDER), supported wider access for the morning-after pill, according to FDA commissioner Margaret Hamburg.
CDER found "there is adequate and reasonable, well-supported, and science-based evidence that Plan B One-Step is safe and effective and should be approved for nonprescription use for all females of child-bearing potential," she said in a statement.
However, Health and Human Services Secretary Kathleen Sebelius disagreed with the FDA decision, and invoked her authority to block the supplement for non-prescription use for females under 17.
"It is common knowledge that there are significant cognitive and behavioral differences between older adolescent girls and the youngest girls of reproductive age," Sebelius said in a statement.
"Because I do not believe enough data were presented to support the application to make Plan B One-Step available over the counter for all girls of reproductive age, I have directed FDA to issue a complete response letter denying the supplemental new drug application."
That meant the drug's status would remain unchanged -- available without a prescription to women 17 and older and by prescription only for younger girls.
"Secretary Kathleen Sebelius was right," said Jeanne Monahan, spokeswoman for the Family Research Council, a well-known conservative group in the United States.
"The availability of Plan B over-the-counter for all ages would have bypassed necessary routine medical care for sexually active girls," she said, citing the risk of STDs and sexual abuse.
"Finally, Plan B can act in a way that can destroy life by preventing implantation. Women of all ages have the right to know how this drug may act in their bodies and on their newly developing babies."
The pill contains 1.5 milligrams of levonorgestrel, a higher level of a hormone found in birth control pills.
Plan B One-Step was first approved in 2009 for use without a prescription in those aged 17 and over, but was available to younger girls with a doctor's prescription.
"We commend the FDA for making the recommendation to approve providing women with increased over-the-counter (OTC) access to Plan B One-Step," said a statement by Teva spokeswoman Denise Bradley.
"And we are disappointed that at this late date, the Department of Health and Human Services has come to a different conclusion."
Kirsten Moore, president of the Reproductive Health Technologies Project, an advocacy group that had supported drugstore shelf access for all ages, expressed anger at President Barack Obama's administration.
"We are outraged that this administration has let politics trump science. There is no rationale for this move. This is unprecedented as evidenced by the commissioner's own letter. Unbelievable," she said.
The National Organization for Women called the move "a stunning betrayal of women."
(c) 2011 AFP
-
US mulls easier access to emergency contraception
Dec 06, 2011 |
not rated yet |
0
-
FDA OKs morning-after pill retail sale
Aug 24, 2006 |
not rated yet |
0
-
U.S. sales of morning-after pill double
Jul 13, 2007 |
not rated yet |
0
-
A new type of pill for emergency contraception
Oct 05, 2010 |
not rated yet |
0
-
FDA panel to consider new 'morning-after pill'
Jun 08, 2010 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
How can there be villous adenoma in colon, if there are no villi there
14 hours ago
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
3 hours ago |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
5 hours ago |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
11 hours ago |
not rated yet |
0
Succesful results in developing oral vaccine against diarrhea
The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.
Medications
13 hours ago |
not rated yet |
0
New sleeping pill poised to hit US markets
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Medications
May 21, 2013 |
4.2 / 5 (5) |
0
Slowing the aging process—only with antibiotics
Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.
Researchers complete largest genetic sequencing study of human disease
Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.
Brain can be trained in compassion, study shows
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
Having both migraines, depression may mean smaller brain
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
Novel approach for influenza vaccination shows promise in early animal testing
A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...
Enzyme-activating antibodies revealed as marker for most severe form of rheumatoid arthritis
In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe ...